Table 5 Subgroup analyses of cancer-specific survival
Subgroup | NO. of studies | HR (95% CI) | P | Heterogeneity | Model | |
|---|---|---|---|---|---|---|
I2 (%) | Ph | |||||
Cancer type | ||||||
RCC | 5 | 2.67 (1.87–3.81) | < 0.001 | 0.0 | 0.453 | Fixed |
UC | 4 | 1.68 (1.09–2.59) | 0.019 | 59.5 | 0.060 | Random |
Cancer stage | ||||||
Non-metastatic | 6 | 2.45 (1.44–4.17) | 0.001 | 66.4 | 0.011 | Random |
Metastatic | 1 | 5.96 (0.67–53.01) | 0.109 | – | – | – |
Mixed | 2 | 1.74 (1.32–2.31) | < 0.001 | 0.0 | 0.721 | Fixed |
Treatment | ||||||
Surgery | 8 | 2.10 (1.51–2.92) | < 0.001 | 54.7 | 0.031 | Random |
Target therapy | 1 | 5.96 (0.67–53.01) | 0.109 | – | – | – |
Sample size | ||||||
> 400 | 5 | 1.77 (1.41–2.20) | < 0.001 | 38.2 | 0.166 | Fixed |
< 400 | 4 | 2.83 (1.23–6.50) | 0.014 | 64.6 | 0.037 | Random |
Cuf-off | ||||||
3 | 3 | 2.66 (1.13–6.27) | 0.026 | 77.4 | 0.012 | Random |
≤ 2 | 6 | 1.85 (1.45–2.35) | < 0.001 | 34.4 | 0.178 | Fixed |
Population | ||||||
Asian | 8 | 1.82 (1.49–2.23) | < 0.001 | 48.5 | 0.059 | Fixed |
African | 1 | 4.66 (1.62–13.39) | 0.004 | – | – | – |